Program
GC203
A development code. Also written as “GC203 TIL”, “GC203 TIL(gene-edited TIL) or autologous TILs” and “Engineering Tumor Infiltrating Lymphocytes”.
Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms, led by Shanghai Juncell Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Juncell Therapeutics | 44 open or running | phase 1since Apr 16, 2024 | Apr 16, 2024 | Nov 30, 2026phase 1 · NCT07256756 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2024First study: phase 1 study in Breast NeoplasmsFirst studyNCT06375187 · 18 planned · China
- Jun 27, 2024Early phase 1 study in Advanced Solid TumorNCT06488950 · 30 planned · China
- Feb 10, 2025Early phase 1 study in Pancreatic NeoplasmsNCT06828328 · 10 planned · China
- Nov 20, 2025Phase 1 study in Solid Tumors, AdultNCT07256756 · 8 planned · China
Ahead
- Nov 1, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT06375187
- Nov 30, 2026Primary completion: phase 1 study in Solid Tumors, AdultNCT07256756
- Jan 31, 2028Primary completion: early phase 1 study in Pancreatic NeoplasmsNCT06828328
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07256756Solid Tumors, Adult · China | 1 | Recruiting | Nov 30, 2026 | 8 |
| NCT06828328Pancreatic Neoplasms · China | Early 1 | Recruiting | Jan 31, 2028 | 10 |
| NCT06488950Advanced Solid Tumor · China | Early 1 | Recruiting | Jun 30, 2026 | 30 |
| NCT06375187Breast Neoplasms · China | 1 | Recruiting | Nov 1, 2026 | 18 |
How it is read
Names in the registry
- “GC203 TIL”, 2 entries
- “GC203 TIL(gene-edited TIL) or autologous TILs”, 1 entry
- “Engineering Tumor Infiltrating Lymphocytes”, 1 entry
Codes read as this program: GC203.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.